Repeat tenecteplase for early ischemic stroke with medium or large vessel blockage
Official title: Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours of Onset With Tenecteplase (RITIS-TNK2): a Prospective, Randomized, Open Label, Blinded Assessment of Outcome, and Multi-center Study
Run by General Hospital of Shenyang Military Region · NCT07375966 · Data updated 2026-11-12
This trial will try giving a second dose of the clot-busting drug tenecteplase to adults with ischemic stroke from medium or large vessel blockages who still have an occlusion one hour after the first dose and are within 4.5 hours of symptom onset.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 198 (estimated) |
| Sponsor | General Hospital of Shenyang Military Region Academic / other |
| Locations | 1 site (Shenyang, Liaoning) |
| Status | Recruiting |
| Started | March 25, 2026 |
| Main results expected | December 30, 2027 |
| Study ends | December 30, 2027 |
| Registry record updated | April 1, 2026 |
| Trial ID | NCT07375966 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with acute ischemic stroke due to confirmed medium or large vessel occlusion who received standard IV thrombolysis within 4.5 hours, have NIHSS ≥4 and acceptable baseline imaging, and show persistent occlusion without significant neurological improvement one hour after the first dose.
✕Probably not a fit
Patients with small-vessel strokes, those who improved substantially after the first thrombolysis, those with intracranial hemorrhage on follow-up imaging, or those with a planned thrombectomy are unlikely to benefit from a repeat dose.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 2 interventional study tests a rescue strategy of repeated intravenous tenecteplase in patients with imaging-confirmed medium or large vessel occlusion who do not show significant improvement one hour after standard thrombolysis. Eligible adults must have received standard-dose IV thrombolysis within 4.5 hours, have measurable deficits (NIHSS ≥4) and acceptable baseline imaging scores (ASPECTS/pc-ASPECTS ≥6 or Pontine-Midbrain Index ≤2). Follow-up vascular imaging at one hour must confirm persistent occlusion and exclude intracranial hemorrhage before administering a second tenecteplase dose. The goal is to increase early recanalization and clinical improvement, particularly where endovascular therapy is not planned or available.
Why it matters
Potential benefit: If successful, a second dose of tenecteplase could increase early artery reopening and improve recovery for patients who do not respond to the first thrombolysis or who cannot access thrombectomy.
How similar studies have gone: Tenecteplase has been shown to be non-inferior to alteplase for initial thrombolysis, but using a second systemic dose as a rescue for persistent medium or large vessel occlusion is a novel approach with limited previous data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 year; * Acute ischemic stroke presumably caused by large or medium vessel occlusion within 4.5 hours of onset, having received standard-dose intravenous thrombolysis, and with no planned thrombectomy; * Measurable neurological deficit before the first intravenous thrombolysis, with NIHSS ≥ 4; * Baseline pc-ASPECTS/ASPECTS ≥ 6, and for posterior circulation infarction, a Pontine-Midbrain Index ≤ 2 (assessed by CT or DWI); * No significant clinical improvement (reduction in NIHSS ≤ 2) or neurological deterioration after initial improvement at 1 hour after the first thrombolysis; * Follow-up imaging (CTA or MRA) at 1 hour after the first thrombolysis rules out intracranial hemorrhage and confirms the presence of large or medium vessel occlusion (internal carotid artery, M1-M3 segments of the middle cerebral artery, A1-A3 segments of the anterior cerebral artery, P1-P3 segments of the posterior cerebral artery, basilar artery or V4 segment of the vertebral artery, PICA, AICA, or SCA); * The second intravenous thrombolysis can be administered within 6 hours of onset; * First stroke onset or past stroke without obvious neurological deficit (mRS≤1); * Signed informed consent. Exclusion Criteria: * Planed for endovascular treatment; * Significant white matter hyperintensities (Fazekas score 3); * Any coagulation abnormality before the first thrombolysis, including INR \> 1.5; * Receipt of dual antiplatelet therapy within 24 hours prior to thrombolysis.; * Pregnancy; * Allergy to the investigational drug(s); * Comorbidity with other serious diseases; * Participating in other clinical trials within 3 months; * Patients not suitable for the study considered by researcher.
Where it's running
-
Lu Wang
Shenyang, Liaoning, China Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AI-based tools to help diagnose, treat and predict stroke outcomes across multiple hospitals
This study tests AI-powered tools on real-world stroke patients to see if they can improve pre-hospital triage, diagnosis, and outcome prediction while data stay securely within each hospital.
-
Remote ischemic conditioning for post-stroke insomnia
A 136-person, randomized study will test whether a non-invasive arm-cuff procedure done twice daily for 90 days can improve sleep after a first ischemic stroke in adults 18–80.
-
Ear-based nerve stimulation to help sleep after a stroke
A device that delivers vagal nerve stimulation through the ear is tested to see if it helps stroke patients in rehab sleep better.
-
Theta Burst Stimulation to Help Stroke Recovery (Upper and Lower Limbs)
This trial tests whether applying theta burst stimulation to the motor cortex, in combination with standard rehabilitation, helps people over 45 who recently had a first ischemic stroke recover arm and leg movement.
-
Preventing another ischemic stroke with a smart bracelet and app
This study tests whether a digital prevention program using a wearable and a mobile app can help people who recently had an ischemic stroke reduce the chance of another stroke and improve risk-factor control.
-
Photon-counting CT to check intracranial stents
This study tests whether ultra-high-resolution photon-counting CT can reliably visualize intracranial stents and detect in-stent restenosis during follow-up of patients with prior stents.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.